Cancer Pancreatic cancer is a highly lethal digestive malignancy with a 5-year survival rate of 10%. So far, the available therapeutic strategies are scarce and the few advancements made, as is the case of poly(ADP-ribose) polymerase (PARP) inhibitors, are …

… fifth annual Michael Manna Memorial Pancreatic Cancer Charity Hockey Game. The Eagles … and donations will benefit the Pancreatic Cancer Research Lab at Weill Cornell … when he received his chemo treatment. He credits Dr. Siolas for …

… critical factor in pancreatic cancer progression, offering new avenues for treatment through targeted … a promising target for PDAC drug therapies, according to senior … candidate drugs to begin the journey toward blocking MICAL2 function in pancreatic cancer …

… been experimentally linked to pancreatic cancer. Subscribe to Technology … target for PDAC drug therapies, according to … cancer and thus current treatments are woefully inadequate,” … drugs to begin the journey toward blocking MICAL2 function in pancreatic cancer …

… promising target for PDAC drug therapies, according to … Moores Cancer Center. “Pancreatic cancer has the highest … cancer and thus current treatments are woefully inadequate,” … drugs to begin the journey toward blocking MICAL2 function in pancreatic cancer …

… . The potential for developing specific drugs that can effectively inhibit MICAL2 … to provide patients battling pancreatic cancer with improved treatment options and more hopeful …

… of Robotic Surgery in Pancreatic Cancer Treatment Minimally Invasive ApproachTraditional pancreatic cancer surgeries often require … , robotic-assisted surgery is transforming pancreatic cancer treatment outcomes. As technology continues to …

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role …

… -VEGFR, several antiangiogenic drugs are developed to inhibitor … appropriately select drug combinations, determine dosages and treatment cycles, … . N Engl J Med. 1971;285(21):1182 … targeting tumor angiogenesis in pancreatic cancer: current dilemmas and …

… . “We anticipate submitting a new drug application to the National Medical … -cell therapy also received orphan drug designation from the FDA for … prior lines of treatment; or pathologically diagnosed advanced pancreatic cancer that progressed after …